Compositions and methods for combination pharmacological treatments to induce a prolonged, mild decrease in core body temperature

Abstract

The present invention is directed to combination pharmacological treatments that induce a prolonged, modest decrease in core body temperature, to the range of −95° F. to −98.5° F. (−35° C. to −36.7° C.) to mitigate and delay the early onset and progression of fatal disease processes associated with premature aging, such as those characteristic of progeria (Hutchinson-Gilford Progeria Syndrome, HGPS), Wiedemann-Rautenstrauch syndrome (neonatal progeroid syndrome), Werner syndrome, and other rare disorders characterized by premature aging, and to prolong the shortened lifespan of children afflicted with these diseases. Short-term chronic administration of the pharmaceutical treatments to a person suffering from mild concussion may also have value in ameliorating neurological damage/symptoms associated with mild concussion. Chronic administration of the pharmacological treatments may also have value in normal human populations or in high-risk human populations. Similar benefits may be realized in other mammals such as canines, felines and other non-human species.